Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaprazan Glurate vs Lansoprazole in Maintenance of Healing in Healed Erosive Esophagitis
NCT07313774Phase 3Withdrawn
- Sponsor
- Cinclus Pharma
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of linaprazan glurate in erosive esophagitis (EE), gastroesophageal reflux disease (GERD), sponsored by Cinclus Pharma. Planned start Mar 2026; status: withdrawn.
02
Drugs
linaprazan glurate
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07313774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313774.